Phase 2 Readout~quarter
Phase 2 Readout: fid-007
- Company
- Fulgent Genetics Inc. (FLGT)
- Drug
- fid-007
- Indication
- recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.